JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target Astria is using its half-life extension technology to develop long-acting mAbs targeting “de-risked targets in large, proven markets,” the analyst tells investors in a research note. The firm says the company’s lead candidate, navenibart, which is starting Phase 3 testing to prevent hereditary angioedema attacks, is addressing a “proven, blockbuster market.” JMP says navenibart has a de-risked mechanism with extended durability.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria initiates Phase 1a Trial of STAR-0310 trial, sees proof of concept in Q3
- Astria Therapeutics designs ALPHA-ORBIT Phase 3 trial of navenibart in HAE
- Astria Therapeutics Unveils Phase 3 Trial for Navenibart
- Astria Therapeutics Expands Stock Incentive Plan
- Astria Therapeutics price target raised to $32 from $28 at Oppenheimer